TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.
Drugs born for fragile X could help some kids with autism, but we still need solid trials.
01Research in Context
What this study did
Kagan and the team wrote a story-style review in 2012.
They looked at fragile X drugs like Arbaclofen and mGluR5 blockers.
They asked, “Could these pills help kids with autism even if they don’t have fragile X?”
What they found
The review says the brain pathways hurt in fragile X overlap with some autism cases.
So a pill that fixes one might ease social or learning problems in the other.
How this fits with other research
Valdovinos (2007) said the same drugs make sense for fragile X, but only talked about that one condition. Kagan widens the lens to autism.
Rojahn et al. (2012), printed the same year, warns that robot therapy for autism is still “maybe later.” Kagan’s drug idea and the robot caution both push for tight testing before use.
Zhou et al. (2025) later showed XR tech gives medium gains for preschoolers with autism. Their meta-analysis is the kind of hard numbers Kagan’s review said we still needed for any targeted treatment.
Why it matters
You may hear parents ask about “fragile X pills” for autism. This paper gives you the science line: the idea is promising, but the proof is not in yet. Keep watching new trials and stay with your ABA plan until strong data arrive.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a note in parent hand-outs: “Fragile X drugs for autism are experimental—ask the doctor before any change.”
02At a glance
03Original abstract
Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABA(B) agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X -associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism.
Research in autism spectrum disorders, 2012 · doi:10.1155/2011/297153